<DOC>
	<DOCNO>NCT00000916</DOCNO>
	<brief_summary>This study compare safety effectiveness continue current anti-HIV medication add switch anti-HIV medication . It follow effect medication change , include addition hydroxyurea ( HU ) , long-term viral suppression . Other medication may add include didanosine ( ddI ) and/or stavudine ( d4T ) . Patients receive combination antiretroviral therapy indinavir ( IDV ) , zidovudine ( ZDV ) ( d4T ) lamivudine ( 3TC ) show viral suppression two year . Discontinuation one two drug result prompt loss viral suppression . Other study show addition HU reverse transcriptase inhibitor treatment result increase antiviral effect . This study provide information effect add HU treatment regimen respect long-term viral suppression .</brief_summary>
	<brief_title>A Study Safety Effectiveness Hydroxyurea Patients Potent Antiretroviral Therapy Who Have Less Than 200 Copies/ml HIV RNA Their Blood</brief_title>
	<detailed_description>Previous ACTG study show discontinuation one two three-drug regimen ( IDV , ZDV , 3TC ) lead prompt loss viral suppression plasma . In trial , determine whether add hydroxyurea ( HU ) suppressive regimen increase long term viral suppression . Important safety information tolerance HU regimen characterize asymptomatic patient viral suppression . Patients equally randomize one three arm receive treatment follow : Arm A : IDV plus ddI plus d4T plus HU placebo . Arm B : IDV plus ddI plus d4T plus HU . Arm C : IDV plus 3TC/ZDV ( d4T plus 3TC ) . Patients monitor every 8 week plasma HIV RNA level CD4 cell count .</detailed_description>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Hydroxyurea</mesh_term>
	<mesh_term>Stavudine</mesh_term>
	<mesh_term>Didanosine</mesh_term>
	<mesh_term>Zidovudine</mesh_term>
	<mesh_term>Indinavir</mesh_term>
	<mesh_term>Lamivudine</mesh_term>
	<mesh_term>Lamivudine , zidovudine drug combination</mesh_term>
	<criteria>Inclusion Criteria You may eligible study : Are 13 year old . Have document HIV1 infection . Are currently receive combine IDV , ZDV ( D4T ) , 3TC least 6 consecutive month , result HIV RNA le 200 copies/ml CD4 cell count great 200 cells/mm3 . Had CD4 count great 100 cells/mm3 start current antiHIV therapy . Are childbearing age agree practice abstinence use combine barrier hormonal method birth control 3 month study . Exclusion Criteria You eligible study : Have take various medication various laboratory result ( see technical abstract ) . Have cancer require chemotherapy . Have unexplained fever 7 day diarrhea 15 day month start study . Had prior peripheral neuropathy hepatitis . Recently underwent radiation , experimental , infection therapy . Are pregnant breastfeeding .</criteria>
	<gender>All</gender>
	<minimum_age>13 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2012</verification_date>
	<keyword>Drug Therapy , Combination</keyword>
	<keyword>HIV Protease Inhibitors</keyword>
	<keyword>Hydroxyurea</keyword>
	<keyword>Reverse Transcriptase Inhibitors</keyword>
	<keyword>Anti-HIV Agents</keyword>
	<keyword>Viral Load</keyword>
</DOC>